Cite
HARVARD Citation
Barok, M. et al. (2020). ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer. Cancer letters. pp. 156-163. [Online].